GLP-1 Drugs for Type 2 Diabetes: Comprehensive Efficacy and Safety Overview | Research

The takeaway

Overview reviews the complete efficacy and safety profile of GLP-1 receptor agonists for type 2 diabetes management, covering all approved agents and their comparative profiles.

Complete GLP-1 comparison
All approved GLP-1 drugs compared for blood sugar, weight, heart, and kidney outcomes to guide individualized T2D treatment

What the researchers found

GLP-1 drugs are established as multi-benefit T2D therapies with varying efficacy profiles across agents, supporting individualized drug selection.

Why it matters

With multiple GLP-1 drugs available, understanding their comparative profiles is essential for choosing the right one for each patient.

The numbers in context

Not specified — review synthesizes available clinical evidence across multiple studies.

How the study worked

Comprehensive review of GLP-1 RA efficacy and safety across all approved agents for T2D.

Who was studied

Type 2 diabetes patients using GLP-1 receptor agonists across clinical studies

What this study cannot tell us

Head-to-head trials between all GLP-1 drugs are limited. Review reflects current evidence that may evolve.

How to read the evidence

Strong evidence: comprehensive review of clinical trial data for all approved GLP-1 agents.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs are now the most important drug class in T2D management, surpassing older agents in both efficacy and multi-organ benefit. This review provides the definitive comparison.

Questions still open

Which GLP-1 drug has the best overall risk-benefit profile?
Should cost or efficacy drive GLP-1 drug selection?
When will biosimilar GLP-1 drugs increase access?

Common questions

Which GLP-1 drug is best for type 2 diabetes?

Semaglutide generally has the strongest evidence across blood sugar, weight, heart, and kidney outcomes. However, "best" depends on individual factors: tirzepatide may be better for weight, oral semaglutide avoids injections, and once-weekly options maximize convenience.

Are all GLP-1 drugs basically the same?

No — they differ meaningfully in potency, weight loss, cardiovascular evidence, dosing frequency, and route. Semaglutide, liraglutide, dulaglutide, and exenatide each have distinct profiles. Your doctor can help choose based on your priorities.

Read the original research

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health? a narrative review of clinical studies.

Endocrine, 89(1), 30-38

View on PubMed ↗Publisher’s paper ↗

Citation

Al Refaie, Antonella; Baldassini, Leonardo; Mondillo, Caterina; Gonnelli, Sara; Ceccarelli, Elena; Tarquini, Roberto; Gonnelli, Stefano; Gennari, Luigi; Caffarelli, Carla. (2025). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health? a narrative review of clinical studies.. Endocrine, 89(1), 30-38. https://doi.org/10.1007/s12020-025-04253-4